已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.

医学 索拉非尼 贝伐单抗 阿替唑单抗 肝细胞癌 内科学 肿瘤科 中期分析 阶段(地层学) 全身疗法 肝细胞癌 瑞戈非尼 临床研究阶段 随机对照试验 实体瘤疗效评价标准 临床试验 完全响应 胃肠病学 总体生存率 伦瓦提尼 外科 无容量 癌症 护理标准 耐火材料(行星科学) 不利影响 肝癌 癌 放射科 抗体 催眠药 联合疗法 化疗 耐受性
作者
Peter R. Galle,Jordi Bruix,Roman Kloeckner,Joerg Trojan,Thomas J. Vogl,Tom Ludde,Pietro Lampertico,Jean‐Charles Nault,Mohamed Bouattour,Thorsten Oliver Goetze,Philippe Merle,Anna Lena Saborowski,M. Peck-Radosavljevic,Vikas S Ostwal,Matthias Pinter,Alessandra Auriemma,Masatoshi Kudo,María Reig,Salah-Eddin Al-Batran,Friedrich Foerster
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (2_suppl): 478-478 被引量:3
标识
DOI:10.1200/jco.2026.44.2_suppl.478
摘要

478 Background: Hepatocellular carcinoma (HCC) is among the most common and deadliest cancers worldwide. Locoregional treatment (LRT) with transarterial chemoembolization (TACE) is standard of care (soc) for intermediate stage (BCLC B) HCC. The IMbrave150 phase 3 study demonstrated that combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF antibody bevacizumab (atezo/bev) extends survival compared to sorafenib in first-line treatment of advanced and intermediate stage HCC failing/unsuited for TACE which has led to its approval in this setting. However, it is unknown if atezo/bev is more efficacious than TACE in patients with intermediate stage HCC patients who would be treated with TACE per soc. While several trials assess the benefit of adding systemic therapy to TACE vs. TACE alone, the ABC-HCC trial directly compares the efficacy and safety of systemic treatment with atezo/bev vs. TACE. ABC-HCC is using a group sequential design with two planned interim analyses (IA) at 33% and 66% information time to assess efficacy/futility. Methods: ABC-HCC is an international phase 3b, randomized, multicenter, open-label, investigator-initiated trial directly comparing atezo/bev vs. TACE in intermediate stage HCC or HCC with indication for TACE according to the treating physician. 320 patients with confirmed HCC (not amenable to curative surgery/ablation, liver transplantation, but amenable to TACE, no extrahepatic spread, no macrovascular invasion except for Vp1/2, ECOG ≤ 1, Child-Pugh A/B7) are randomized (1:1) to receive either systemic treatment (Arm A: atezo, 1,200 mg IV; bev, 15 mg/kg IV; Q3W; max. 24 months) or TACE (Arm B: on demand as long as TACEable as assessed by the investigator). Imaging (CT/MRI) is performed Q8W to determine the primary endpoint time to failure of treatment strategy (TTFS: Time from randomization until death or need for a further therapeutic option). Here, we report on the first efficacy/futility IA at 33% information time (85 events). Results: To date, 206 pts have been enrolled at 54 centers in Austria, France, Germany, India, Italy, Japan and Spain. At data cut-off (06/13/2025), 194 pts were randomized, of whom 168 pts had a follow up duration of ≥ 3 months and were included in the IA (Arm A: 87; Arm B: 81). 100 events were observed for the primary endpoint TTFS (Arm A: 44; Arm B: 56). Median TTFS was 14.6 months in Arm A vs. 9.5 months in Arm B with a HR of 0.55 (95% CI [0.36, 0.83]). Based on these results, the trial was continued. Conclusions: The results of the first IA provide important insights into the efficacy of atezo/bev vs. TACE in intermediate stage HCC and suggest a superiority of systemic therapy compared to TACE in regard to TTFS. Based on these findings, the trial is progressing to the second IA at 66% information time (169 events). Clinical trial information: 2024-512953-26-00 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
代维健的大黑完成签到,获得积分10
1秒前
坚强飞兰完成签到 ,获得积分10
2秒前
Lu完成签到,获得积分10
5秒前
沈平灵发布了新的文献求助10
6秒前
无花果的应助被LH采纳,获得10
7秒前
独特的修洁完成签到 ,获得积分10
8秒前
FashionBoy的应助被Luminous采纳,获得10
9秒前
Zhang完成签到,获得积分10
11秒前
哈哈哈哈哈完成签到,获得积分10
11秒前
12秒前
华仔的应助被沈平灵采纳,获得10
15秒前
小白完成签到,获得积分10
15秒前
18秒前
19秒前
z104发布了新的文献求助10
19秒前
嘻嘻哈哈的应助被小白采纳,获得10
20秒前
Her完成签到 ,获得积分10
20秒前
慕青的应助被楠楠采纳,获得10
22秒前
Hello的应助被DearWhite采纳,获得10
24秒前
24秒前
LH发布了新的文献求助10
24秒前
Pz迷惑完成签到,获得积分10
25秒前
林夏发布了新的文献求助10
25秒前
Her关注了科研通微信公众号
25秒前
嘻嘻哈哈的应助被小白采纳,获得10
28秒前
大模型的应助被结实的半双采纳,获得10
28秒前
研友_85rJEL完成签到 ,获得积分10
28秒前
28秒前
吱吱吱吱完成签到 ,获得积分10
29秒前
29秒前
29秒前
31秒前
34秒前
楠楠发布了新的文献求助10
34秒前
甜菜图书馆完成签到,获得积分10
35秒前
专注向雪完成签到 ,获得积分10
37秒前
zhaoxx完成签到 ,获得积分10
37秒前
微笑大神发布了新的文献求助10
38秒前
38秒前
XHQ完成签到 ,获得积分10
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189808
求助须知:如何正确求助?哪些是违规求助? 9576985
关于积分的说明 21850907
捐赠科研通 7787770
什么是DOI,文献DOI怎么找? 3435793
关于科研通互助平台的介绍 2559825
邀请新用户注册赠送积分活动 2482680